In the clinic, breast tumors have been deemed ERα-positive (ER+ tumors) if more than 1% of epithelial cells demonstrate nuclear staining in immunohistochemistry with anti-hERα antibodies, qualifying patients for hormonal therapies, although rates of response are much lower for tumors with low expression of ERα [74]. This evidence concerns the gene ESR1 and breast neoplasm.